Login
PFIZER INC logo

PFIZER INC

pfizer.com

What Do They Do?

Develops, manufactures and sells biopharmaceutical medicines and vaccines to wholesalers, hospitals and government agencies.

How Do They Make Money?

Pfizer earns most revenue from biopharmaceutical product sales. It typically ships or delivers products first, with payment on short-term credit according to market payment cycles.

revenue
SegmentShareRevenue
Pfizer CentreOne
2.1%
FY2022: 1.3%
Pfizer Ignite
0.1%
FY2022: <0.1%

Who Are Their Customers?

Pfizer sells prescription medicines mainly through wholesalers, and directly to healthcare providers and government buyers. It sells vaccines mainly to government agencies and healthcare institutions, directly or through wholesalers and pharmacies.

Do Revenues Turn Into Profits?

Yes. It kept 12 cents of every revenue dollar as net income in FY2025 and turned 15 cents into free cash flow.

Operating income, FY2025
23% of revenue
▲ +15% vs FY2024 ($12.4B, 20%)
Net income, FY2025
12% of revenue
▼ −3% vs FY2024 ($8B, 13%)
Free cash flow, FY2025
15% of revenue
▼ −8% vs FY2024 ($9.8B, 15%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 27, 2026
Revenue
▼ 0%
vs $16.7B in Q3 FY2025
Net income
▼ −8%
vs $3.5B in Q3 FY2025
Pfizer CentreOne share of revenue vs 100.0% in Q3 FY2025
  • Aug 4, 2026 Pfizer raised its full-year revenue guidance midpoint The midpoint rose by $500 million, to a range of $60.5 billion to $62.5 billion.
  • Jun 18, 2026 CFO Dave Denton plans to leave; Cecile Guegan will become interim CFO Guegan will serve while Pfizer searches for Denton's successor.

Shrinking. Revenue fell 23% in 4 years, from $81.3B in FY2021 to $62.6B in FY2025, about 6% a year.

Paxlovid sales channels Paxlovid sales shifted from government agencies toward commercial channels: the earlier business described sales mainly to government agencies, while sales later moved to commercial markets in the U.S. and mostly commercial channels internationally.

Biotech R&D services The business added Pfizer Ignite, an end-to-end R&D service for selected biotech companies, then decided to discontinue and wind it down.

Revenue over time
Pfizer CentreOne Pfizer Ignite
$200B$100B$0

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support